10-Q: DaVita Q2 2025: Revenue Up, Debt Rises, Cyber Impact

DaVita Inc. reports increased total revenues for Q2 2025 and year-to-date, alongside higher debt and ongoing impacts from a recent cybersecurity incident.

Summary

• Total revenues for the three months ended June 30, 2025, were $3,379,526 thousand, up from $3,186,722 thousand in the same period of 2024.
• Total revenues for the six months ended June 30, 2025, were $6,603,055 thousand, up from $6,257,277 thousand in the same period of 2024.
• Net income attributable to DaVita Inc. for the three months ended June 30, 2025, was $199,337 thousand, down from $222,676 thousand in 2024.
• Net income attributable to DaVita Inc. for the six months ended June 30, 2025, was $362,254 thousand, down from $462,325 thousand in 2024.
• Diluted net income per share was $2.58 for Q2 2025 (vs. $2.50 in Q2 2024) and $4.57 for YTD Q2 2025 (vs. $5.15 in YTD Q2 2024).
• U.S. dialysis treatments increased by 2.1% to 7,186,217 for Q2 2025 compared to Q1 2025, but decreased by 1.3% to 14,226,736 for YTD Q2 2025 compared to YTD Q2 2024.
• Average patient service revenue per treatment for U.S. dialysis was $404.58 for Q2 2025 and $402.38 for YTD Q2 2025.
• Total debt principal outstanding increased to $10,330,478 thousand as of June 30, 2025, from $9,511,106 thousand as of December 31, 2024.
• The company incurred approximately $13.5 million in charges related to a cybersecurity incident in Q2 2025, impacting patient care costs ($1.0 million) and general and administrative expenses ($12.5 million).
• Free cash flow for the six months ended June 30, 2025, was $112 thousand, a significant decrease from $327 thousand in the same period of 2024.
• Acquired the dialysis operations of Fresenius Medical Care AG and its affiliates in Brazil for initial aggregate consideration of approximately $94,000 thousand, effective August 1, 2025.

Sentiment

Score: 4

Explanation: While revenue increased, net income and EPS declined, and free cash flow significantly decreased. The company is facing headwinds from a cybersecurity incident, higher debt costs, and potential adverse regulatory changes regarding commercial payors. The increase in debt and the decline in profitability and cash flow indicate a challenging financial period despite revenue growth.

Positives

• Total revenues increased for both the three and six months ended June 30, 2025, compared to prior periods, indicating top-line growth.
• U.S. dialysis average patient service revenue per treatment increased due to normal seasonal improvements, including patients meeting co-insurance and deductibles, and the incorporation of phosphate binders into the ESRD PPS bundle.
• International operating income significantly increased for both the three and six months ended June 30, 2025, driven by acquired and non-acquired treatment growth and favorable changes in contingent consideration fair value.
• Improvements were observed in certain labor-related costs, such as training and productivity, with expectations for continued improvements due to reduced turnover.
• Successfully refinanced Term Loan B-1 with a repriced Term Loan B-2 facility, including an incremental borrowing of $250,000, and used proceeds to prepay a proportionate amount of Term Loan A-1.
• The One Big Beautiful Bill Act (OBBBA) makes permanent 100% bonus depreciation and domestic research cost expensing, which could be beneficial for future tax liabilities.

Negatives

• Net income attributable to DaVita Inc. decreased for both the three and six months ended June 30, 2025, compared to prior periods.
• Diluted EPS decreased for the six months ended June 30, 2025, compared to the same period in 2024.
• U.S. dialysis treatments for the six months ended June 30, 2025, decreased by 1.3% year-over-year, primarily due to higher patient mortality and missed treatments from a more severe flu season.
• Operating income decreased for the six months ended June 30, 2025, compared to the same period in 2024.
• Debt expense significantly increased due to a higher long-term debt balance and an increase in the weighted average effective interest rate.
• Free cash flow decreased significantly by 65.7% for the six months ended June 30, 2025, compared to the same period in 2024.
• A cybersecurity incident caused disruption to operations, billing, and revenue collection cycles, and incurred $13.5 million in remediation charges in Q2 2025.
• Corporate administrative support expenses increased due to higher long-term incentive compensation and professional fees.
• The expiration of enhanced premium tax credits for ACA exchanges at the end of 2025 is expected to reduce enrollment in commercial health insurance, which would have an adverse impact on the business, results of operations, financial condition, and cash flows.

Risks

• External conditions, including general economic, marketplace, and global health conditions, such as inflation, interest rate volatility, labor market challenges, and increased patient mortality rates, could have a material adverse impact.
• The concentration of profits generated by higher-paying commercial payor plans faces continued downward pressure on average realized payment rates.
• A potential reduction in the number or percentage of patients under commercial plans due to legislative efforts (e.g., OBBBA) or restrictive plan designs by payors.
• Risks arising from potential changes in or new laws, regulations, or requirements applicable to the company, including those related to healthcare, privacy, antitrust matters, and labor matters.
• Challenges in successfully implementing strategies for Integrated Kidney Care (IKC), Value-Based Care (VBC) initiatives, and home-based dialysis in a complex and highly regulated environment.
• A reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid, or other government-based programs, and the impact of the Medicare Advantage benchmark structure.
• Reliance on significant suppliers, service providers, and other third-party vendors, with risks of closure, reduction, or disruption in their services or products.
• Noncompliance with privacy or security laws or any security breach, such as the recent cybersecurity incident, could lead to litigation, regulatory actions, reputational harm, and financial impact.
• Challenges in attracting, retaining, and motivating teammates, including key leadership personnel, and managing potential disruptions from union organizing activities or labor market volatility.
• Changes in pharmaceutical practice patterns, reimbursement and payment policies, or pharmaceutical pricing.
• Ability to develop and maintain relationships with physicians and hospitals, and the emergence of new models of care that may erode the patient base and impact reimbursement rates.
• Ability to complete and successfully integrate acquisitions, mergers, dispositions, joint ventures, or other strategic transactions on favorable terms or at all.
• Variability of cash flows, including potential extended billing or collections cycles due to defects or operational issues in billing systems or services of third parties.
• The effects of natural or other disasters, public health crises, or severe adverse weather events.
• Factors that may impact the ability to repurchase stock under the share repurchase program and the timing of any such repurchases.
• Evolving regulatory requirements affecting environmental, social, and governance (ESG) standards, measurements, and reporting requirements.
• Ongoing legal proceedings and governmental investigations, including those by the U.S. Attorney New Jersey, California Department of Insurance, District of Columbia Office of Attorney General, and Federal Trade Commission, as well as an antitrust class action suit.

Future Outlook

The company expects continued impact from global economic conditions, political and regulatory developments, and inflationary pressures, leading to increased expenses, particularly staffing and labor costs. However, improvements in labor-related costs due to reduced turnover are anticipated. The expiration of enhanced premium tax credits for ACA exchanges at the end of 2025 is likely to reduce enrollment in commercial health insurance, which would adversely impact the business. CMS estimates a 1.9% increase in ESRD freestanding facilities average reimbursement for calendar year 2026.

Management Comments

• "We believe that the aforementioned recent developments and general economic, marketplace and global health conditions will continue to impact the Company in the future. Their ultimate impact depends on future developments that are highly uncertain and difficult to predict."
• "Based on information currently available, we believe that this incident has not had, and is not expected to have, a material adverse impact on our business, results of operations or financial condition. However, we do not yet know the full impact of the cybersecurity incident, including how much of the financial impact will be covered by insurance."
• "We believe that our cash flow from operations and other sources of liquidity, including from amounts available under our senior secured credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months."

Industry Context

The dialysis industry faces ongoing challenges from government payment rates, particularly Medicare and Medicaid, and the impact of the Medicare Advantage benchmark structure. Regulatory adjustments are continuous, as evidenced by the incorporation of phosphate binders into the ESRD PPS bundle and the proposed 1.9% increase in ESRD freestanding facilities average reimbursement for 2026. The potential expiration of ACA enhanced premium tax credits could shift patients from higher-paying commercial plans to lower-paying government plans, impacting the industry's revenue mix. The sector is also experiencing increased union organizing activities and ongoing labor market volatility, contributing to elevated staffing and labor costs.

Comparison to Industry Standards

• The acquisition of Fresenius Medical Care AG's dialysis operations in Brazil highlights the competitive landscape within the global dialysis market, where major players like DaVita and Fresenius are actively consolidating and expanding.
• The Centers for Medicare & Medicaid Services (CMS) proposed rule for a 1.9% increase in ESRD freestanding facilities average reimbursement for calendar year 2026 provides a key industry benchmark for government reimbursement rates, which are critical for dialysis providers.
• The company's average patient service revenue per treatment ($404.58 in Q2 2025) and patient care costs per treatment ($268.36 in Q2 2025) are internal metrics that would typically be benchmarked against industry averages, though specific comparable company data is not provided in the filing.
• The company's strategic focus on Integrated Kidney Care (IKC) and Value-Based Care (VBC) initiatives aligns with broader healthcare industry trends towards more holistic, outcome-based patient management and risk-sharing models, similar to those adopted by other large healthcare providers.

Legal Proceedings

• **2020 U.S. Attorney New Jersey Investigation**: Subpoena and Civil Investigative Demand related to joint venture arrangements, medical director agreements, and Corporate Integrity Agreement compliance. A private party relator filed a fourth amended complaint on November 8, 2023, which the court denied a motion to dismiss on April 29, 2025. The Company answered the complaint on July 21, 2025, and intends to defend the action.
• **2020 California Department of Insurance Investigation**: Investigative Subpoena regarding patient communications about insurance plans, financial assistance from American Kidney Fund (AKF), and donations to AKF.
• **2023 District of Columbia Office of Attorney General Investigation**: Civil Investigative Demand in connection with an antitrust investigation into the AKF, covering communications with AKF, donations, and patient/provider/insurer communications regarding AKF.
• **2024 Federal Trade Commission Investigation**: Two Civil Investigative Demands regarding the acquisition of medical director services and provision of dialysis services, seeking information on restrictive covenants with physicians.
• **2021 Antitrust Indictment and Putative Class Action Suit**: Indictment alleging agreements not to solicit senior-level employees violated Section 1 of the Sherman Act. The Company and former CEO were acquitted on April 15, 2022. A consolidated putative class action complaint was filed on August 9, 2021, and a Third Amended Complaint was filed on October 27, 2024, which the Company responded to on December 20, 2024. The Company disputes allegations and intends to defend.

Related Party Transactions

• Share repurchase agreement with Berkshire Hathaway Inc. As of June 30, 2025, a repurchase obligation of $100,336 thousand was recorded as 'Due to related party.' This obligation increased subsequent to June 30, 2025, and was settled on August 1, 2025, for 1,636 shares at $230,025 thousand.

Stakeholder Impact

• **Shareholders**: Experienced decreased net income and EPS, a significant decrease in free cash flow, and increased debt, despite ongoing share repurchases.
• **Patients**: Faced higher mortality and missed treatments due to a severe flu season, potential impact from the cybersecurity incident on Personally Identifiable Information (PII) and Protected Health Information (PHI), and potential changes in insurance coverage due to the One Big Beautiful Bill Act (OBBBA).
• **Employees**: Encountered increased staffing and labor costs, ongoing challenges with elevated teammate turnover, and increased union organizing activities.
• **Payors**: Subject to changes in government payment rates (Medicare, Medicaid), the impact of the Medicare Advantage benchmark structure, and potential shifts in commercial payor mix due to OBBBA.
• **Suppliers/Vendors**: Reliance on significant suppliers and service providers, with risks from disruptions, as exemplified by the cybersecurity incident affecting Change Healthcare.
• **Creditors**: The company's long-term debt increased, though management believes current liquidity is sufficient to fund debt service obligations.

Next Steps

• Continue assessing the potential impact of the One Big Beautiful Bill Act (OBBBA) and other federal and state legislative and regulatory efforts on the business.
• Implement the OBBBA provisions, with several having effective dates in 2027 and 2028.
• Continue to incur expenses for investigation and remediation activities related to the cybersecurity incident.
• Monitor potential future risks and uncertainties from the cybersecurity incident, including litigation, reputational harm, and regulatory actions.
• CMS proposed rule to update Medicare ESRD PPS payment rate and policies for calendar year 2026.
• Quarterly principal payments for Term Loan B-2 begin on September 30, 2025.
• The company expects to add additional service offerings and pursue additional strategic initiatives in the future.
• The company expects to continue to see improvements in labor-related costs due to reduced turnover.

Key Dates

Recommendation

While DaVita shows revenue growth and strategic acquisitions (Brazil), the significant decline in net income, EPS, and free cash flow, coupled with rising debt and ongoing cybersecurity and regulatory challenges, presents a mixed picture. The company is actively managing its debt and labor costs, but the uncertainties surrounding government policy changes (OBBBA, ACA tax credits) and the lingering effects of the cybersecurity incident suggest a period of consolidation rather than strong growth. The stock may be range-bound until these headwinds clear or clear positive catalysts emerge.

Keywords

Dialysis, Kidney Care, Healthcare, SEC Filing, 10-Q, Financial Results, Revenue, Net Income, Debt, Cybersecurity, Patient Services, Integrated Kidney Care, Value-Based Care, Share Repurchase, Government Regulation, Medicare, Medicaid, Commercial Payors, Brazil Acquisition, Interest Rates